Glyx Therapeutics and SATT Nord Make Their Exclusive License Official, and Glyx Features in the Regional Media

October 2026 — Amiens, France Glyx Therapeutics has an exclusive license agreement with SATT Nord (Société d’Accélération du Transfert de Technologies Nord), signed on April 21, 2026, covering the European patent family EP21306658 / WO2023094699 and the associated know-how. On October 13, 2026, the agreement was officially celebrated with the directors of the universities concerned, […]

More

Glyx Therapeutics Joins the Brain&Mind Community

October 2026 — Amiens, France Glyx Therapeutics has joined the Brain&Mind community, a strategic step in the development of our molecules targeting tauopathies. What this brings to Glyx Access to a network of experts specialized in neuroscience and neurodegenerative diseases Synergies with other players engaged in research on cognitive disorders Collaboration opportunities to accelerate the […]

More

Glyx Therapeutics at the Morning Session “Financing Your Innovation: From Idea to Market”

September 29, 2026 — Hauts-de-France, France Glyx Therapeutics took part in the morning session “Financing your innovation: from idea to market”, held at Eurasanté with Banque Populaire du Nord. Financing a biotech company, from the idea to the market, is a demanding path. Exchanges with the health and finance ecosystem are valuable to build a […]

More

Green Chemistry at Glyx Therapeutics: Join Us at the Sustainable Day in Amiens on November 5, 2026

September 2026 — Amiens, France At Glyx Therapeutics, our molecule, an anionic lipidic oligosaccharide, targets Alzheimer’s disease and tauopathies. Our innovation does not stop there: we are developing the production of this molecule at pharmaceutical (GMP) grade, entirely following green chemistry principles, with electrosynthesis and mechanosynthesis. Sustainable Day, Amiens, November 5, 2026 Glyx Therapeutics will […]

More

Glyx Therapeutics Selected as a Finalist of the i-Lab 2026 Innovation Competition

September 2026 — Amiens, France Glyx Therapeutics has been selected as a finalist of the i-Lab 2026 innovation competition, which supports the creation of deeptech companies from public research results and is backed by the France 2030 programme. Recognition for an early-stage biotech Created in December 2025, Glyx Therapeutics is developing a small molecule, administered […]

More

Glyx Therapeutics Awarded the French Tech Emergence Deeptech Grant

May 2026 — Amiens, France Glyx Therapeutics is a laureate of the French Tech Emergence Deeptech grant, awarded with the support of the Hauts-de-France Region, Amiens Métropole and Bpifrance. The grant amounts to €90,000. What it will allow Accelerate the development of our research work Strengthen our innovation capacity Advance high-impact projects against Alzheimer’s disease […]

More

Glyx Therapeutics Joins Spartners by Servier & BioLabs

May 2026 — Paris-Saclay, France Glyx Therapeutics has joined Spartners by Servier & BioLabs, the biotech incubator located on Servier’s research site in Paris-Saclay (Gif-sur-Yvette), where it has a lab bench and a workstation. BioLabs France welcomed Glyx as one of its newest members, highlighting its research-driven mindset and its commitment to advancing science for […]

More